Wednesday, February 18, 2009

Pharmos Announces Agreement to Sell Certain CB2 Selective Agonists

Pharmos Corporation announced today that it has entered into an agreement with an Israel based company, Reperio Pharmaceuticals Ltd. (Reperio) for the sale of the patent rights and technical know how related to the compound known as PRS-639,058 and some follow on molecules.

The details can be read here.

No comments: